

Takahiro Watanabe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5865043/publications.pdf>

Version: 2024-02-01

31
papers

627
citations

687363

13
h-index

642732

23
g-index

34
all docs

34
docs citations

34
times ranked

635
citing authors

#	ARTICLE	IF	CITATIONS
1	Defective Epstein-Barr virus in chronic active infection and haematological malignancy. <i>Nature Microbiology</i> , 2019, 4, 404-413.	13.3	152
2	Molecular Basis of Epstein-Barr Virus Latency Establishment and Lytic Reactivation. <i>Viruses</i> , 2021, 13, 2344.	3.3	70
3	Epstein-Barr Virus BKRFB4 Gene Product Is Required for Efficient Progeny Production. <i>Journal of Virology</i> , 2017, 91, .	3.4	35
4	Tofacitinib induces G1 cell-cycle arrest and inhibits tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells. <i>Oncotarget</i> , 2016, 7, 76793-76805.	1.8	32
5	Direct Evidence of Abortive Lytic Infection-Mediated Establishment of Epstein-Barr Virus Latency During B-Cell Infection. <i>Frontiers in Microbiology</i> , 2020, 11, 575255.	3.5	27
6	The Epstein-Barr Virus BDLF4 Gene Is Required for Efficient Expression of Viral Late Lytic Genes. <i>Journal of Virology</i> , 2015, 89, 10120-10124.	3.4	24
7	Oncogenesis of CAEBV revealed: Intragenic deletions in the viral genome and leaky expression of lytic genes. <i>Reviews in Medical Virology</i> , 2020, 30, e2095.	8.3	24
8	S-Like-Phase Cyclin-Dependent Kinases Stabilize the Epstein-Barr Virus BDLF4 Protein To Temporally Control Late Gene Transcription. <i>Journal of Virology</i> , 2019, 93, .	3.4	21
9	RNAseq analysis identifies involvement of EBNA2 in PD-L1 induction during Epstein-Barr virus infection of primary B cells. <i>Virology</i> , 2021, 557, 44-54.	2.4	18
10	The heat shock protein 90 inhibitor BIIB021 suppresses the growth of T and natural killer cell lymphomas. <i>Frontiers in Microbiology</i> , 2015, 6, 280.	3.5	17
11	Oncolytic activity of HF10 in head and neck squamous cell carcinomas. <i>Cancer Gene Therapy</i> , 2020, 27, 585-598.	4.6	16
12	Induction of Epstein-Barr Virus Oncoprotein LMP1 by Transcription Factors AP-2 and Early B Cell Factor. <i>Journal of Virology</i> , 2016, 90, 3873-3889.	3.4	14
13	Initial Characterization of the Epstein-Barr Virus BSRF1 Gene Product. <i>Viruses</i> , 2019, 11, 285.	3.3	14
14	The Epstein-Barr virus BRRF2 gene product is involved in viral progeny production. <i>Virology</i> , 2015, 484, 33-40.	2.4	13
15	Deletion of Viral microRNAs in the Oncogenesis of Epstein-Barr Virus-Associated Lymphoma. <i>Frontiers in Microbiology</i> , 2021, 12, 667968.	3.5	12
16	Antitumor activity of cyclin-dependent kinase inhibitor alsterpaullone in Epstein-Barr virus-associated lymphoproliferative disorders. <i>Cancer Science</i> , 2020, 111, 279-287.	3.9	12
17	Roles of Epstein-Barr virus BGLF3.5 gene and two upstream open reading frames in lytic viral replication in HEK293 cells. <i>Virology</i> , 2015, 483, 44-53.	2.4	11
18	EBV Exploits RNA m6A Modification to Promote Cell Survival and Progeny Virus Production During Lytic Cycle. <i>Frontiers in Microbiology</i> , 0, 13, .	3.5	11

#	ARTICLE	IF	CITATIONS
19	A Herpesvirus Specific Motif of Epstein-Barr Virus DNA Polymerase Is Required for the Efficient Lytic Genome Synthesis. <i>Scientific Reports</i> , 2015, 5, 11767.	3.3	10
20	Epstein-Barr Virus BBRF2 Is Required for Maximum Infectivity. <i>Microorganisms</i> , 2019, 7, 705.	3.6	10
21	The Epstein-Barr Virus BRRF1 Gene Is Dispensable for Viral Replication in HEK293 cells and Transformation. <i>Scientific Reports</i> , 2017, 7, 6044.	3.3	9
22	Antitumor effects of duvelisib on Epstein-Barr virus-associated lymphoma cells. <i>Cancer Medicine</i> , 2018, 7, 1275-1284.	2.8	9
23	The BOLF1 gene is necessary for effective Epstein-Barr viral infectivity. <i>Virology</i> , 2019, 531, 114-125.	2.4	9
24	Role of Epstein-Barr Virus C Promoter Deletion in Diffuse Large B Cell Lymphoma. <i>Cancers</i> , 2021, 13, 561.	3.7	9
25	Epstein-Barr virus tegument protein BGLF2 in exosomes released from virus-producing cells facilitates de novo infection. <i>Cell Communication and Signaling</i> , 2022, 20, .	6.5	9
26	PD-L1 upregulation by lytic induction of Epstein-Barr Virus. <i>Virology</i> , 2022, 568, 31-40.	2.4	8
27	The C-Terminus of Epstein-Barr Virus BRRF2 Is Required for its Proper Localization and Efficient Virus Production. <i>Frontiers in Microbiology</i> , 2017, 8, 125.	3.5	7
28	A STING inhibitor suppresses EBV-induced B cell transformation and lymphomagenesis. <i>Cancer Science</i> , 2021, 112, 5088-5099.	3.9	7
29	Oncolytic activity of naturally attenuated herpes-simplex virus HF10 against an immunocompetent model of oral carcinoma. <i>Molecular Therapy - Oncolytics</i> , 2021, 20, 220-227.	4.4	6
30	Characterization of a Suppressive Cis-acting Element in the Epstein-Barr Virus LMP1 Promoter. <i>Frontiers in Microbiology</i> , 2017, 8, 2302.	3.5	3
31	Comprehensive Analyses of Intraviral Epstein-Barr Virus Protein-Protein Interactions Hint Central Role of BLRF2 in the Tegument Network. <i>Journal of Virology</i> , 2022, 96, .	3.4	3